Acceleron Pharma

Investors & Media

<< Back
Mar 07, 2007

Acceleron Pharma to Present at the Cowen 27th Annual Health Care Conference

Acceleron Pharma to Present at the Cowen 27th Annual Health Care Conference

CAMBRIDGE, MA – March 7, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel biotherapeutics, today announced that Steven Ertel, Vice President Business Development, will provide a corporate presentation at the Cowen and Company 27th Annual Health Care Conference on Thursday March 15, 2007 at 9:30 a.m. (EST).  The conference will be held at the Boston Marriott Copley Place Hotel, Boston, MA.

About Acceleron Pharma

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases.  Acceleron’s scientific approach takes advantage of its unique insight on the regenerative powers of two protein families: the Growth and Differentiation Factor (GDF) and Bone Morphogenetic Protein (BMP) families.  The company’s lead program is an anabolic bone agent being developed to reverse bone loss in diseases such as osteoporosis and cancer.  Additionally, the company is advancing several preclinical programs that increase muscle mass, control angiogenesis and inhibit fat accumulation.  Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs.  The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock Associates.

Contact: Steven Ertel, Vice President Business Development, Acceleron Pharma, tel: 617-576-2220 x234 and Paul Kidwell (Media) Kidwell PR, tel: 617-296-3854